CVTX Phase II CVT-510 fibrillation data

CV Therapeutics (CVTX) said its CVT-510 adenosine A1 receptor antagonist significantly reduced heart rate from baseline (p<0.05) without decreasing blood pressure in its ongoing open-label, dose-rangi...